Remsima - direct healthcare professional communication (DHPC)

infliximab

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC) : Remsima (infliximab): New IV formulation (100 mg and 350 mg concentrate for solution for infusion) contains sorbitol and is therefore contraindicated in patients with hereditary fructose intolerance

Dissemination date: 08/12/2025

Key facts

• Medicine name:
  Remsima
• Active substance:
  infliximab
• Therapeutic area (MeSH):
  • Arthritis, Psoriatic
  • Spondylitis, Ankylosing
  • Colitis, Ulcerative
  • Psoriasis
  • Crohn Disease
  • Arthritis, Rheumatoid
• Procedure number:
  X-149
• Regulatory outcome:
  Variation
• DHPC type:
  New contraindication
• Human ATC codes:
  L04AB02
• Dissemination date:
  08/12/2025